Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
22 nov. 2024 18h23 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
22 nov. 2024 17h00 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
CORRECTION - Elevai Labs Inc.
14 nov. 2024 14h35 HE
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14 nov. 2024 09h08 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
04 nov. 2024 17h45 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22 oct. 2024 09h54 HE
|
Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21 oct. 2024 07h30 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
04 oct. 2024 17h08 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03 oct. 2024 15h45 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03 oct. 2024 07h30 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,